EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

SciSparc Ltd (SPRC) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of SciSparc Ltd $3.58, price $5.01, upside -28.5%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home Israel · ISIN IL0010951403

SL SciSparc Ltd logo Thin data Sep 23, 2026

SciSparc Ltd

SPRC · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $3.58 · Overvalued (−29%)
!Quality 49/100
!Weak Growth (revenue 5y +9.3 %/yr)
!negative free cash flow
!Mixed vs. peers (3/6)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch SciSparc Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$37,838 $3.06 Fair Value $3.58 Aug 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $3.06 – $37,838 · fair‑value band $2.36 – $4.48 · the $5.01 price screens above the $3.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow SciSparc in your weekly email

Every Wednesday you see whether SciSparc is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.

Show more

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Stock analysis

SciSparc Ltd (SPRC) currently trades at $5.01, while our model-based Fair Value estimate is $3.58, implying the stock looks roughly 39.9% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 81/100, which puts the evidence level at low.

Scenario range: $2.36 (bear) to $4.48 (bull), the price of $5.01 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

SciSparc Ltd reported revenue of $856K in FY2025 versus $1.1M in FY2021, a compound −5.4%/yr. Reported net income was −$12.2M in FY2025.

Key figures

Market cap $3.8M · P/E ratio 0.1 · P/S ratio 4.40 · EPS (TTM) $94.83 · Return on equity −178% · Return on assets (EBIT) −73.0% · Operating margin −849% · Revenue (TTM) $856K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 91% below its 52-week high and 64% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −29%, SPRC screens richer than that median.

Fair Value models

Bear $2.36 Fair Value $3.58 Bull $4.48
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($71.74 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $3.70 $4.95 $7.39 51
All 1 models by family
Asset-Based
NCAV (Graham) $3.70 $4.95 $7.39 51

Open the full fair value analysis →

Notify me when SPRC reaches fair value

Put SPRC on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 49/100

Of which business quality 49 · Market factors (momentum, volatility) 14

Profitability 3
Margins and returns on capital today
Quality Growth 29
Are margins and returns improving?
Cashflow 25
Earnings quality: real cash, not paper profit
Fin. Strength 70
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 19/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−34.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.3%
Start year 2020 (pandemic)
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−598.7% (2020) → −1,022.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SPRC screens 40% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare SciSparc Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 49 · Above median
Fair Value upside −22% · Above median
Profitability
Return on assets −61% · Bottom 25%
Growth and dividend
Revenue growth −35% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 0.1× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BeOne Medicines AG ONC $368.08 $280.94 −24%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SciSparc Ltd · Fair Value
$3.58 −40%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SciSparc Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SPRC

Frequently asked questions

Is SciSparc Ltd (SPRC) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $3.58 versus a price of $5.01, about −29% upside (overvalued).
What is the fair value of SPRC?
Our model-based fair value for SciSparc Ltd is $3.58 (as of Sep 23, 2026), built from audited fundamentals. The current price: $5.01.
What is the quality score of SPRC?
SciSparc Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SciSparc Ltd (SPRC)?
Our model-based price target is the fair value of $3.58 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $2.36, optimistic scenario $4.48. It is a calculation from audited fundamentals, not an analyst target.
What is the SciSparc Ltd stock forecast for 2026?
Our models put fair value at $3.58, about −29% upside versus a price of $5.01 (overvalued). Cautious scenario $2.36, optimistic scenario $4.48. The calculation is refreshed regularly with new filings.
What is the revenue of SciSparc Ltd (SPRC)?
SciSparc Ltd reported trailing-twelve-month revenue of about $856K (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of SciSparc Ltd (SPRC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SciSparc Ltd it is $3.58 per share (as of Sep 23, 2026), against a price of $5.01. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is SciSparc Ltd stock overvalued or undervalued in 2026?
As of Sep 23, 2026, SPRC trades above its calculated fair value: price $5.01, fair value $3.58, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SPRC?
No. The price is what the market pays today ($5.01); the fair value is what the company's own numbers justify ($3.58). For SciSparc Ltd the two are $1.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is SciSparc Ltd worth?
The market values SciSparc Ltd at about $3.8M (market capitalisation, as of Sep 23, 2026). Per share that is $5.01; our models calculate a fair value of $3.58 per share.
What do the bullish and bearish scenarios say about SPRC?
Our models span a range for SciSparc Ltd: cautious scenario $2.36, base $3.58, optimistic $4.48 per share (as of Sep 23, 2026, price $5.01). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SPRC?
SciSparc Ltd trades at a price-to-earnings ratio of 0.1 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.58 is built from several models across several years.
How solid is the balance sheet of SciSparc Ltd (SPRC)?
Balance-sheet figures for SciSparc Ltd (as of Sep 23, 2026): return on equity −178.4%. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is SPRC from its 52-week high?
SciSparc Ltd trades at $5.01, about 91% below its 52-week high of $54.81 and 64% above the low of $3.06 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $3.58 is for.
Which stocks are comparable to SciSparc Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SciSparc Ltd stock attractive at the current price?
The data as of Sep 23, 2026: price $5.01, calculated fair value $3.58 (−29%), Quality Score 49/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SPRC calculated?
We run SciSparc Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.58, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. SciSparc Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SciSparc Ltd (SPRC)?
The closing price on Sep 23, 2026 was $5.01. Our model-based fair value is $3.58, about −29% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SciSparc Ltd right now?
The price sits above even our optimistic bull case ($4.48). The favourable scenario is already priced in. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($2.36 to $4.48) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of SciSparc Ltd

How large is the market capitalisation of SciSparc Ltd (SPRC)?
The market capitalisation of SciSparc Ltd is $3.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SciSparc Ltd (SPRC)?
The price-to-sales ratio of SciSparc Ltd is 4.40 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SciSparc Ltd (SPRC)?
Earnings per share at SciSparc Ltd are $94.83 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of SciSparc Ltd (SPRC)?
The return on equity (ROE) of SciSparc Ltd is −178% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SciSparc Ltd (SPRC)?
On an EBIT basis the return on assets of SciSparc Ltd is −73.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SciSparc Ltd (SPRC)?
The operating margin of SciSparc Ltd is −849% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SciSparc Ltd (SPRC)?
Revenue at SciSparc Ltd is growing −34.5% versus a year earlier (3y avg −14.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SciSparc Ltd (SPRC) generate?
The free cash flow of SciSparc Ltd is −$4.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does SciSparc Ltd (SPRC) hold?
SciSparc Ltd holds more cash than debt, $4.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SciSparc Ltd in the live analysis

One click puts SciSparc Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.